Amubarvimab, previously known as BI 196, represents a significant advancement in therapeutic development, particularly concerning its potential to neutralize COVID-19. This monoclonal antibody demonstrates https://bookmarks-hit.com/story25849748/amubarvimab-a-deep-exploration-into-the-antibody-s-prospects